Aurinia Announces Results of Annual General Meeting
22 June 2017 - 9:30PM
Business Wire
Aurinia Pharmaceuticals Inc. (“Aurinia” or the
“Company”) (NASDAQ: AUPH / TSX: AUP) is pleased to announce
that the six incumbent directors of the Company were elected at the
Company’s annual general meeting held on June 21, 2017 (the
“Meeting”).
Detailed results of the vote by proxy for the election of
directors are provided below:
Votes For (%)
Votes Withheld (%)
Nominee
Election of Directors
Richard Glickman
96.70%
3.30%
Benjamin Rovinski
99.09%
0.91%
David Jayne
71.78%
28.22%
Hyuek Joon Lee
98.95%
1.05%
Lorin Randall
75.43%
24.57%
George Milne
99.11%
0.89%
Voting results on all matters voted on at the Meeting will be
filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.
About Aurinia
Aurinia is a clinical stage biopharmaceutical company focused on
developing and commercializing therapies to treat targeted patient
populations that are suffering from serious diseases with a high
unmet medical need. The Company is currently developing
voclosporin, an investigational drug, for the treatment of LN. The
Company is headquartered in Victoria, BC and focuses its
development efforts globally.
We seek Safe Harbor.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170622006109/en/
Aurinia Pharmaceuticals Inc.Investor Contact:Celia
EconomidesVice President, Public
Affairsceconomides@auriniapharma.com